Wells Fargo & Company Cingulate Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.52 - $0.98 $8 - $15	16 Added 27.59%	74 $0
Q2 2023 Aug 15, 2023	BUY	$0.84 - $1.12 $3 - $4	4 Added 7.41%	58 $0
Q1 2023 May 12, 2023	BUY	$0.91 - $1.85 $0 - $1	1 Added 1.89%	54 $0
Q4 2022 Feb 13, 2023	BUY	$0.69 - $328.8 $0 - $328	1 Added 1.92%	53 $0
Q3 2022 Nov 14, 2022	BUY	$0.26 - $420.0 $6 - $10,080	24 Added 85.71%	52 $0
Q2 2022 Aug 12, 2022	BUY	$259.2 - $453.6 $518 - $907	2 Added 7.69%	28 $0
Q1 2022 May 16, 2022	BUY	$278.4 - $698.4 $7,238 - $18,158	26 New	26 $0

Ticker CING
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,309,400
Market Cap $53.8M
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.